한글목차

일본의 세포 및 유전자 치료 시장의 시장 규모는 2024년에 7억 2,700만 달러에 달했습니다. 향후 IMARC Group은 시장이 2033년까지 20억 1,600만 달러에 달하며, 2025-2033년 12%의 성장률(CAGR)을 보일 것으로 예측하고 있습니다. 만성질환 및 유전성 질환의 증가에 의해 이러한 헬스케어 과제에 대처할 수 있는 첨단 치료제에 대한 수요가 높아지고 있으며, 이것이 주로 시장 성장을 촉진하고 있습니다.

본 리포트에서 답변하는 주요 질문

• 일본의 세포 및 유전자 치료 시장은 지금까지 어떻게 추이하며, 향후 어떻게 추이하는가?
• COVID-19가 일본의 세포 및 유전자 치료 시장에 미친 영향은?
• 일본의 세포 및 유전자 치료 시장의 치료 유형별 내역은?
• 일본의 세포 및 유전자 치료 시장의 적응증별 내역은?
• 일본의 세포 및 유전자 치료 시장의 투여 형태별 내역은?
• 일본의 세포 및 유전자 치료 시장의 최종사용자별 내역은?
• 일본의 세포 및 유전자 치료 시장의 밸류체인에는 어떤 단계가 있는가?
• 일본의 세포 및 유전자 치료의 주요 촉진요인과 과제는 무엇인가?
• 일본의 세포 및 유전자 치료 시장의 구조와 주요 기업은?
• 일본의 세포 및 유전자 치료 시장에서 경쟁의 정도는?

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사의 목적
• 이해관계자
• 데이터 소스
• 시장 추정
• 조사 방법

제3장 개요

제4장 일본의 세포 및 유전자 치료 시장 : 서론

• 개요
• 시장 역학
• 업계 동향
• 경쟁 정보

제5장 일본의 세포 및 유전자 치료 시장 구도

• 과거 및 현재 시장 동향(2019-2024년)
• 시장 예측(2025-2033)

제6장 일본의 세포 및 유전자 치료 시장 : 치료 유형별 내역

• 세포치료
• 유전자 치료

제7장 일본의 세포 및 유전자 치료 시장 : 적응증별 내역

• 심혈관질환
• 종양 질환
• 유전성 질환
• 감염증
• 신경질환
• 기타

제8장 일본의 세포 및 유전자 치료 시장 : 딜리버리 모드별 내역

• 생체내
• 생체외

제9장 일본의 세포 및 유전자 치료 시장 : 최종사용자별 내역

• 병원
• 암케어 센터
• 제약·바이오테크놀러지 기업
• 기타

제10장 일본의 세포 및 유전자 치료 시장 : 경쟁 구도

• 개요
• 시장 구조
• 시장 기업 포지셔닝
• 주요 성공 전략
• 경쟁 대시보드
• 기업 평가 상한

제11장 주요 기업의 개요

제12장 일본의 세포 및 유전자 치료 시장 : 업계 분석

• 촉진요인·억제요인·기회
• Porter's Five Forces 분석
• 밸류체인 분석

제13장 부록

영문목차

Japan cell and gene therapy market size reached USD 727 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,016 Million by 2033, exhibiting a growth rate (CAGR) of 12% during 2025-2033. The increasing adoption of chronic and genetic diseases is propelling the demand for advanced therapies capable of addressing these healthcare challenges, which is primarily driving the market growth.

Cell and gene therapy are cutting-edge medical approaches that hold immense promise for the treatment of various diseases and conditions. In essence, cell therapy involves the transplantation or manipulation of living cells to replace or repair damaged or malfunctioning tissues within the body. This can include the use of stem cells to regenerate damaged organs or tissues. On the other hand, gene therapy focuses on modifying or correcting faulty genes responsible for causing diseases. This can be achieved by introducing, replacing, or repairing specific genes within a patient's cells. Both cell and gene therapy are at the forefront of personalized medicine, offering the potential to provide targeted, individualized treatments that can address the root causes of diseases, rather than just managing their symptoms. These innovative therapies have shown remarkable success in clinical trials and are paving the way for a new era in healthcare, with the potential to revolutionize the treatment of genetic disorders, cancer, and a range of other challenging medical conditions.

Japan Cell and Gene Therapy Market Trends:

The Japan cell and gene therapy market is rapidly emerging as a dynamic and promising sector within the country's healthcare landscape. With an aging population and a growing burden of chronic diseases, there is a heightened demand for innovative treatments that can offer long-term solutions. Cell and gene therapy have gained significant attention and investment in Japan due to their potential to address unmet medical needs. Japanese researchers and biopharmaceutical companies have been actively engaged in developing novel therapies using these cutting-edge technologies. Regulatory authorities in Japan have also taken steps to facilitate the clinical development and commercialization of cell and gene therapies, making it an attractive market for both domestic and international players. The market's growth is further fueled by collaborations between academia, industry, and healthcare providers, as well as the increasing adoption of precision medicine approaches. As a result, the Japan cell and gene therapy market is poised for continued expansion and is likely to play a pivotal role in the future of healthcare in the country.

Japan Cell and Gene Therapy Market Segmentation:

Therapy Type Insights:

• Cell Therapy
• Stem Cell
• Non-Stem Cell
• Gene Therapy

Indication Insights:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Delivery Mode Insights:

• In-Vivo
• Ex-Vivo

End User Insights:

• Hospitals
• Cancer Care Centers
• Pharmaceutical and Biotechnology Companies
• Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan cell and gene therapy market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan cell and gene therapy market?
• What is the breakup of the Japan cell and gene therapy market on the basis of therapy type?
• What is the breakup of the Japan cell and gene therapy market on the basis of indication?
• What is the breakup of the Japan cell and gene therapy market on the basis of delivery mode?
• What is the breakup of the Japan cell and gene therapy market on the basis of end user?
• What are the various stages in the value chain of the Japan cell and gene therapy market?
• What are the key driving factors and challenges in the Japan cell and gene therapy?
• What is the structure of the Japan cell and gene therapy market and who are the key players?
• What is the degree of competition in the Japan cell and gene therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cell and Gene Therapy Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Cell and Gene Therapy Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Cell and Gene Therapy Market - Breakup by Therapy Type

• 6.1 Cell Therapy
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Segmentation
    • 6.1.3.1 Stem Cell
    • 6.1.3.2 Non-Stem Cell
  • 6.1.4 Market Forecast (2025-2033)
• 6.2 Gene Therapy
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)

7 Japan Cell and Gene Therapy Market - Breakup by Indication

• 7.1 Cardiovascular Disease
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Oncology Disorder
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Genetic Disorder
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)
• 7.4 Infectious Disease
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2019-2024)
  • 7.4.3 Market Forecast (2025-2033)
• 7.5 Neurological Disorder
  • 7.5.1 Overview
  • 7.5.2 Historical and Current Market Trends (2019-2024)
  • 7.5.3 Market Forecast (2025-2033)
• 7.6 Others
  • 7.6.1 Historical and Current Market Trends (2019-2024)
  • 7.6.2 Market Forecast (2025-2033)

8 Japan Cell and Gene Therapy Market - Breakup by Delivery Mode

• 8.1 In-Vivo
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Ex-Vivo
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)

9 Japan Cell and Gene Therapy Market - Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Overview
  • 9.1.2 Historical and Current Market Trends (2019-2024)
  • 9.1.3 Market Forecast (2025-2033)
• 9.2 Cancer Care Centers
  • 9.2.1 Overview
  • 9.2.2 Historical and Current Market Trends (2019-2024)
  • 9.2.3 Market Forecast (2025-2033)
• 9.3 Pharmaceutical and Biotechnology Companies
  • 9.3.1 Overview
  • 9.3.2 Historical and Current Market Trends (2019-2024)
  • 9.3.3 Market Forecast (2025-2033)
• 9.4 Others
  • 9.4.1 Historical and Current Market Trends (2019-2024)
  • 9.4.2 Market Forecast (2025-2033)

10 Japan Cell and Gene Therapy Market - Competitive Landscape

• 10.1 Overview
• 10.2 Market Structure
• 10.3 Market Player Positioning
• 10.4 Top Winning Strategies
• 10.5 Competitive Dashboard
• 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

• 11.1 Company A
  • 11.1.1 Business Overview
  • 11.1.2 Product Portfolio
  • 11.1.3 Business Strategies
  • 11.1.4 SWOT Analysis
  • 11.1.5 Major News and Events
• 11.2 Company B
  • 11.2.1 Business Overview
  • 11.2.2 Product Portfolio
  • 11.2.3 Business Strategies
  • 11.2.4 SWOT Analysis
  • 11.2.5 Major News and Events
• 11.3 Company C
  • 11.3.1 Business Overview
  • 11.3.2 Product Portfolio
  • 11.3.3 Business Strategies
  • 11.3.4 SWOT Analysis
  • 11.3.5 Major News and Events
• 11.4 Company D
  • 11.4.1 Business Overview
  • 11.4.2 Product Portfolio
  • 11.4.3 Business Strategies
  • 11.4.4 SWOT Analysis
  • 11.4.5 Major News and Events
• 11.5 Company E
  • 11.5.1 Business Overview
  • 11.5.2 Product Portfolio
  • 11.5.3 Business Strategies
  • 11.5.4 SWOT Analysis
  • 11.5.5 Major News and Events

12 Japan Cell and Gene Therapy Market - Industry Analysis

• 12.1 Drivers, Restraints, and Opportunities
  • 12.1.1 Overview
  • 12.1.2 Drivers
  • 12.1.3 Restraints
  • 12.1.4 Opportunities
• 12.2 Porters Five Forces Analysis
  • 12.2.1 Overview
  • 12.2.2 Bargaining Power of Buyers
  • 12.2.3 Bargaining Power of Suppliers
  • 12.2.4 Degree of Competition
  • 12.2.5 Threat of New Entrants
  • 12.2.6 Threat of Substitutes
• 12.3 Value Chain Analysis

13 Appendix